Hospira, Celltrion Enter Biogeneric Product Pact

Hospira has signed a business cooperation agreement with South Korea-based Celltrion for future distribution of biogeneric products in the U.S., Europe, Australia, New Zealand and Canada. Celltrion is currently developing eight biogeneric products, five of which relate to Hospira’s pipeline.

The companies will collaborate on manufacturing and supply of the products. Following regulatory approval, Hospira and Celltrion will co-market the drugs, with the products independently commercialized under each company’s brand name. Financial terms were not disclosed.

“Celltrion brings a history of expertise in the manufacturing of protein-based therapeutics,” said Christopher B. Begley, chairman and chief executive officer, Hospira. “This partnership gives Hospira access to Celltrion’s large biogenerics portfolio, and is an excellent example of Hospira’s commitment to organic and inorganic growth. We’re excited to work with Celltrion, and we look forward to expanding Hospira’s presence in these significant biogenerics markets.”

“Hospira is the world leader in generic injectable pharmaceuticals and has the capabilities and experience to successfully sell biogenerics in these important markets,” said Jung-Sin Seo, chief executive officer and chairman, Celltrion. “We believe this partnership will benefit both companies by combining Hospira’s broad outreach with Celltrion’s advanced biologic manufacturing capabilities.”